BTG3 and cholestasis: VCTE, abdominal ultrasound, and autoimmune and virological screening were identified as highly appropriate first‐line tools for diagnosing chronic cholestasis, while genetic studies and MRCP ± EUS were deemed inappropriate for AMA+ or ANA+ cases without cholestasis.